Lusefi (luseogliflozin; Taisho) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism. They prevent filtered glucose from being reabsorbed in the kidney rather than actively facilitating glucose filtration and excretion. Due to this distinct mechanism of action, when SGLT-2 inhibitors are used as monotherapy they do not lower glucose to unsafe levels and thus avoid the risk of hypoglycemia.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Lusefi : Diabetes type 2
LIST OF FIGURES 5 Figure 1: Lusefi sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES 6 Table 1: Lusefi sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.